PRIVIA HEALTH GROUP INC (PRVA) Fundamental Analysis & Valuation

NASDAQ:PRVA • US74276R1023

Current stock price

23.13 USD
+0.01 (+0.04%)
Last:

This PRVA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. PRVA Profitability Analysis

1.1 Basic Checks

  • In the past year PRVA was profitable.
  • In the past year PRVA had a positive cash flow from operations.
  • In multiple years PRVA reported negative net income over the last 5 years.
  • PRVA had a positive operating cash flow in each of the past 5 years.
PRVA Yearly Net Income VS EBIT VS OCF VS FCFPRVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M -200M

1.2 Ratios

  • PRVA has a Return On Assets of 1.67%. This is comparable to the rest of the industry: PRVA outperforms 54.00% of its industry peers.
  • PRVA has a Return On Equity (3.11%) which is in line with its industry peers.
  • PRVA has a Return On Invested Capital (2.75%) which is comparable to the rest of the industry.
  • PRVA had an Average Return On Invested Capital over the past 3 years of 2.17%. This is significantly below the industry average of 8.51%.
  • The last Return On Invested Capital (2.75%) for PRVA is above the 3 year average (2.17%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 1.67%
ROE 3.11%
ROIC 2.75%
ROA(3y)1.75%
ROA(5y)-4.65%
ROE(3y)3.16%
ROE(5y)-7.26%
ROIC(3y)2.17%
ROIC(5y)N/A
PRVA Yearly ROA, ROE, ROICPRVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

1.3 Margins

  • PRVA has a Profit Margin of 1.08%. This is comparable to the rest of the industry: PRVA outperforms 57.00% of its industry peers.
  • In the last couple of years the Profit Margin of PRVA has declined.
  • Looking at the Operating Margin, with a value of 1.61%, PRVA is in line with its industry, outperforming 45.00% of the companies in the same industry.
  • In the last couple of years the Operating Margin of PRVA has declined.
  • PRVA has a Gross Margin of 9.87%. This is in the lower half of the industry: PRVA underperforms 74.00% of its industry peers.
  • In the last couple of years the Gross Margin of PRVA has remained more or less at the same level.
Industry RankSector Rank
OM 1.61%
PM (TTM) 1.08%
GM 9.87%
OM growth 3YN/A
OM growth 5Y-12.3%
PM growth 3YN/A
PM growth 5Y-22.33%
GM growth 3Y-0.24%
GM growth 5Y-0.49%
PRVA Yearly Profit, Operating, Gross MarginsPRVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. PRVA Health Analysis

2.1 Basic Checks

  • PRVA has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for PRVA has been increased compared to 1 year ago.
  • Compared to 5 years ago, PRVA has more shares outstanding
  • PRVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PRVA Yearly Shares OutstandingPRVA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
PRVA Yearly Total Debt VS Total AssetsPRVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • PRVA has an Altman-Z score of 4.53. This indicates that PRVA is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.53, PRVA belongs to the top of the industry, outperforming 83.00% of the companies in the same industry.
  • There is no outstanding debt for PRVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.53
ROIC/WACC0.31
WACC8.94%
PRVA Yearly LT Debt VS Equity VS FCFPRVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.3 Liquidity

  • PRVA has a Current Ratio of 1.60. This is a normal value and indicates that PRVA is financially healthy and should not expect problems in meeting its short term obligations.
  • With a decent Current ratio value of 1.60, PRVA is doing good in the industry, outperforming 64.00% of the companies in the same industry.
  • A Quick Ratio of 1.60 indicates that PRVA should not have too much problems paying its short term obligations.
  • PRVA's Quick ratio of 1.60 is fine compared to the rest of the industry. PRVA outperforms 65.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.6
Quick Ratio 1.6
PRVA Yearly Current Assets VS Current LiabilitesPRVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. PRVA Growth Analysis

3.1 Past

  • PRVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.55%, which is quite impressive.
  • Measured over the past years, PRVA shows a decrease in Earnings Per Share. The EPS has been decreasing by -9.93% on average per year.
  • Looking at the last year, PRVA shows a very strong growth in Revenue. The Revenue has grown by 22.26%.
  • The Revenue has been growing by 21.04% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)54.55%
EPS 3Y9.35%
EPS 5Y-9.93%
EPS Q2Q%133.33%
Revenue 1Y (TTM)22.26%
Revenue growth 3Y16.09%
Revenue growth 5Y21.04%
Sales Q2Q%-31.71%

3.2 Future

  • PRVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 57.08% yearly.
  • The Revenue is expected to grow by 10.44% on average over the next years. This is quite good.
EPS Next Y109.45%
EPS Next 2Y64.03%
EPS Next 3Y57.08%
EPS Next 5YN/A
Revenue Next Year13.79%
Revenue Next 2Y12.12%
Revenue Next 3Y11.91%
Revenue Next 5Y10.44%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
PRVA Yearly Revenue VS EstimatesPRVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B
PRVA Yearly EPS VS EstimatesPRVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

3

4. PRVA Valuation Analysis

4.1 Price/Earnings Ratio

  • PRVA is valuated quite expensively with a Price/Earnings ratio of 136.06.
  • Compared to the rest of the industry, the Price/Earnings ratio of PRVA is on the same level as its industry peers.
  • When comparing the Price/Earnings ratio of PRVA to the average of the S&P500 Index (27.33), we can say PRVA is valued expensively.
  • PRVA is valuated quite expensively with a Price/Forward Earnings ratio of 64.96.
  • PRVA's Price/Forward Earnings ratio is in line with the industry average.
  • The average S&P500 Price/Forward Earnings ratio is at 38.16. PRVA is valued rather expensively when compared to this.
Industry RankSector Rank
PE 136.06
Fwd PE 64.96
PRVA Price Earnings VS Forward Price EarningsPRVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • PRVA's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. PRVA is more expensive than 62.00% of the companies in the same industry.
  • PRVA's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. PRVA is cheaper than 64.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 17.78
EV/EBITDA 54.93
PRVA Per share dataPRVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • PRVA's earnings are expected to grow with 57.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.24
PEG (5Y)N/A
EPS Next 2Y64.03%
EPS Next 3Y57.08%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PRVA Dividend Analysis

5.1 Amount

  • PRVA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PRVA Fundamentals: All Metrics, Ratios and Statistics

PRIVIA HEALTH GROUP INC

NASDAQ:PRVA (4/15/2026, 9:56:36 AM)

23.13

+0.01 (+0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-26
Earnings (Next)05-07
Inst Owners99.13%
Inst Owner Change0.03%
Ins Owners1.81%
Ins Owner Change5.08%
Market Cap2.91B
Revenue(TTM)2.12B
Net Income(TTM)22.92M
Analysts84.29
Price Target33.06 (42.93%)
Short Float %2.11%
Short Ratio2.8
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)43.55%
Min EPS beat(2)-8.97%
Max EPS beat(2)96.08%
EPS beat(4)1
Avg EPS beat(4)-2.92%
Min EPS beat(4)-60.96%
Max EPS beat(4)96.08%
EPS beat(8)1
Avg EPS beat(8)-23.29%
EPS beat(12)3
Avg EPS beat(12)-1.19%
EPS beat(16)6
Avg EPS beat(16)61.33%
Revenue beat(2)1
Avg Revenue beat(2)5.86%
Min Revenue beat(2)-6.18%
Max Revenue beat(2)17.91%
Revenue beat(4)3
Avg Revenue beat(4)4.55%
Min Revenue beat(4)-6.18%
Max Revenue beat(4)17.91%
Revenue beat(8)7
Avg Revenue beat(8)4.33%
Revenue beat(12)10
Avg Revenue beat(12)3.07%
Revenue beat(16)10
Avg Revenue beat(16)-7.25%
PT rev (1m)2.82%
PT rev (3m)2.73%
EPS NQ rev (1m)-3.01%
EPS NQ rev (3m)10.44%
EPS NY rev (1m)1.65%
EPS NY rev (3m)11.12%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)-31.3%
Revenue NY rev (1m)-2.21%
Revenue NY rev (3m)-37.78%
Valuation
Industry RankSector Rank
PE 136.06
Fwd PE 64.96
P/S 1.37
P/FCF 17.78
P/OCF 17.78
P/B 3.94
P/tB 9.33
EV/EBITDA 54.93
EPS(TTM)0.17
EY0.73%
EPS(NY)0.36
Fwd EY1.54%
FCF(TTM)1.3
FCFY5.62%
OCF(TTM)1.3
OCFY5.62%
SpS16.9
BVpS5.87
TBVpS2.48
PEG (NY)1.24
PEG (5Y)N/A
Graham Number4.73788 (-79.52%)
Profitability
Industry RankSector Rank
ROA 1.67%
ROE 3.11%
ROCE 4.27%
ROIC 2.75%
ROICexc 6.87%
ROICexgc N/A
OM 1.61%
PM (TTM) 1.08%
GM 9.87%
FCFM 7.7%
ROA(3y)1.75%
ROA(5y)-4.65%
ROE(3y)3.16%
ROE(5y)-7.26%
ROIC(3y)2.17%
ROIC(5y)N/A
ROICexc(3y)6.14%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)3.37%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5Y-16.37%
OM growth 3YN/A
OM growth 5Y-12.3%
PM growth 3YN/A
PM growth 5Y-22.33%
GM growth 3Y-0.24%
GM growth 5Y-0.49%
F-Score6
Asset Turnover1.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 136.39
Cash Conversion 370.18%
Profit Quality 712.96%
Current Ratio 1.6
Quick Ratio 1.6
Altman-Z 4.53
F-Score6
WACC8.94%
ROIC/WACC0.31
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)607.4%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.55%
EPS 3Y9.35%
EPS 5Y-9.93%
EPS Q2Q%133.33%
EPS Next Y109.45%
EPS Next 2Y64.03%
EPS Next 3Y57.08%
EPS Next 5YN/A
Revenue 1Y (TTM)22.26%
Revenue growth 3Y16.09%
Revenue growth 5Y21.04%
Sales Q2Q%-31.71%
Revenue Next Year13.79%
Revenue Next 2Y12.12%
Revenue Next 3Y11.91%
Revenue Next 5Y10.44%
EBIT growth 1Y101.6%
EBIT growth 3YN/A
EBIT growth 5Y6.15%
EBIT Next Year475.2%
EBIT Next 3Y99.86%
EBIT Next 5Y56.77%
FCF growth 1Y49.53%
FCF growth 3Y51.38%
FCF growth 5Y33.52%
OCF growth 1Y49.53%
OCF growth 3Y51.28%
OCF growth 5Y33.26%

PRIVIA HEALTH GROUP INC / PRVA Fundamental Analysis FAQ

What is the fundamental rating for PRVA stock?

ChartMill assigns a fundamental rating of 5 / 10 to PRVA.


Can you provide the valuation status for PRIVIA HEALTH GROUP INC?

ChartMill assigns a valuation rating of 3 / 10 to PRIVIA HEALTH GROUP INC (PRVA). This can be considered as Overvalued.


What is the profitability of PRVA stock?

PRIVIA HEALTH GROUP INC (PRVA) has a profitability rating of 4 / 10.


What is the earnings growth outlook for PRIVIA HEALTH GROUP INC?

The Earnings per Share (EPS) of PRIVIA HEALTH GROUP INC (PRVA) is expected to grow by 109.45% in the next year.